|
Synmosa Biopharma Corporation is a pharmaceutical company engaged in the research, development, and manufacturing of solid, semi-solid, and liquid dosage forms, including tablets, capsules, granules, dry powder inhalers, ointments, sprays, and injectables. The company also produces medical devices, cosmetics, and functional foods. Its manufacturing capabilities are supported by five technology platforms: effervescent tablet technology, HFA metered-dose inhaler technology, nasal spray technology, sex hormone technology, and granules technology. The company operates a dedicated hormone manufacturing facility that passed PIC/S GMP inspection in 2011. Synmosa Biopharma serves the healthcare sector with products for gastrointestinal disorders and other therapeutic areas, including a recently launched triple-mechanism drug for constipation. The company reports strong revenue growth driven by new product launches and international collaborations. Summarised from the company's own disclosures |
Industry Drug Manufacturers - Specialty & Generic | Homepage synmosa.com.tw |
| Sector Healthcare | IR page synmosa.com.tw/InvestorRelations | |
|
Tags
pharmaceutical manufacturing, solid dosage forms, liquid dosage forms, medical devices, cosmetics, functional foods, effervescent tablets, metered-dose inhalers, nasal sprays, sex hormones, granules, gastroenterology, Effervescent Tablet Technology, HFA MDI Technology, Nasal Spray Technology Platform, Sex Hormone Technology, Granules Technology
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | NT$ 13.788B |
| Market cap (USD) | $ 418.492M |
| P/E | 16.31 |
| PEG | 17.34 |
| P/BV | 1.57 |
| P/S | 1.87 |
| P/OCF | 17.66 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 10.3% |
| ROI | 9.4% |
| ROIC | 6.9% |
| Profit margin | 13.3% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | 0.94% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | 25.0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.189B | 5.55B | 5.14B | 4.386B | 3.235B | 3.038B | 2.68B | 2.363B | 1.861B | 1.865B | 1.776B | 1.476B | 1.249B | 1.067B | 927.806M | 824.706M |
| Net profit | 821.849M | 684.683M | 594.832M | 799.091M | 303.86M | 638.112M | 47.09M | 430.899M | 4.688M | 166.65M | 31.541M | 110.267M | 62.926M | 91.862M | -22.578M | 32.024M |
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 32.4 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/S | 2.63 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial information published on MOPS, newest first, subjects as filed in Chinese, guarantee and loan balance notices and routine equipment purchases included. The link opens the company's material information on MOPS.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Synmosa Biopharma Corporation
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVEE | 0.03% | 48,058 | $ 38.857K | Nov 16, 2026 |
| DEXC | 0.01% | 44,125 | $ 36.872K | Nov 12, 2026 |
| DFEV | 0.01% | 267,646 | $ 223.651K | Nov 12, 2026 |
| DFSE | 0.01% | 56,757 | $ 47.427K | Nov 12, 2026 |
| DFEM | 0.01% | 618,491 | $ 516.824K | Nov 12, 2026 |
| DFAE | 0.00% | 395,194 | $ 330.232K | Nov 12, 2026 |
| DFAX | 0.00% | 374,504 | $ 312.943K | Nov 12, 2026 |